摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl 2-(2-hydroxy-5-methylphenyl)acetate | 41873-67-0

中文名称
——
中文别名
——
英文名称
ethyl 2-(2-hydroxy-5-methylphenyl)acetate
英文别名
Ethyl 2-hydroxy-5-methylbenzeneacetate
ethyl 2-(2-hydroxy-5-methylphenyl)acetate化学式
CAS
41873-67-0
化学式
C11H14O3
mdl
——
分子量
194.23
InChiKey
UZTWZRCCFVYYKJ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    14
  • 可旋转键数:
    4
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

点击查看最新优质反应信息

文献信息

  • Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors
    申请人:BioCryst Pharmaceuticals, Inc.
    公开号:US11021458B2
    公开(公告)日:2021-06-01
    Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
    公开了式 I 和 II 的化合物及其药学上可接受的盐和原药,它们是补体系统的抑制剂。还提供了包含此类化合物的药物组合物,以及使用这些化合物和组合物治疗或预防以补体系统活性异常为特征的疾病或病症的方法。
  • SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS
    申请人:Biocryst Pharmaceuticals, Inc.
    公开号:EP3687506A1
    公开(公告)日:2020-08-05
  • [EN] SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS<br/>[FR] BENZOFURANE, BENZOPYRROLE, BENZOTHIOPHÈNE SUBSTITUÉS ET INHIBITEURS DU COMPLÉMENT STRUCTURELLEMENT APPARENTÉS
    申请人:BIOCRYST PHARM INC
    公开号:WO2019195720A1
    公开(公告)日:2019-10-10
    Disclosed are compounds of formulae I and II, and pharmaceutically acceptable salts and prodrugs thereof, which are inhibitors of the complement system. Also provided are pharmaceutical compositions comprising such a compound, and methods of using the compounds and compositions in the treatment or prevention of a disease or condition characterized by aberrant complement system activity.
查看更多